CIK 0001894562 · <br>Emerging growth company
Prime Medicine, Inc.
Sign in to watch- Ticker
- PRME
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-465-0013
- Business address
- 60 FIRST ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-08 | Gottesdiener Keith Michael See Remarks | Gift | −226,925 | 50,241 | ||
| 2024-10-08 | Gottesdiener Keith Michael See Remarks | Gift | +226,925 | 682,259 | ||
| 2024-06-12 | Marrazzo Jeffrey D Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-06-12 | Schenkein David P Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-06-12 | NELSEN ROBERT Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-06-12 | Kelly Michael Aaron Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-06-12 | Foster-Cheek Kaye I Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-06-12 | Chung Wendy Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-06-12 | Cahill Thomas Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2024-06-05 | Gottesdiener Keith Michael See Remarks | Gift | −250,000 | 2,310,837 | ||
| 2024-06-05 | Gottesdiener Keith Michael See Remarks | Gift | +250,000 | 277,166 | ||
| 2024-05-17 | Reine Allan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-05-17 | Brudnick Richard Chief Business Officer | Grant or award · Stock Option (right to buy) | +19,300 | 38,600 | ||
| 2024-05-17 | LEE ANN L. Chief Technical Officer | Grant or award · Stock Option (right to buy) | +80,416 | 160,832 | ||
| 2024-02-29 | Marrazzo Jeffrey D Director | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-02-25 | Gottesdiener Keith Michael See Remarks | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-02-21 | Brudnick Richard Chief Business Officer | Grant or award · Stock Option (right to buy) | +135,747 | 135,747 | ||
| 2024-02-21 | Duffield Jeremy Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +180,995 | 180,995 | ||
| 2024-02-21 | LEE ANN L. Chief Technical Officer | Grant or award · Stock Option (right to buy) | +180,995 | 180,995 | ||
| 2024-02-21 | Goldwasser Meredith SVP, Strategy & Corporate Ops. | Grant or award · Stock Option (right to buy) | +90,498 | 90,498 |
Page 6 of 13 · 241 trades